When does Pfizer (PFE.DE) release earnings and what matters most

Pfizer (PFE.DE) reports on 03 Feb 2026. Investors should focus on full-year guidance, Comirnaty and Prevnar sales, Paxlovid volume, and margin commentary, which will drive PFE.DE stock moves

What valuation metrics matter for PFE.DE stock

Key metrics for PFE.DE stock include **PE 15.09**, price/Book **1.60**, free cash flow yield near **7.0%**, and dividend sustainability. Watch EPS and FCF trends post-earnings

How does Meyka AI view PFE.DE stock right now

Meyka AI gives PFE.DE a **68.59/100** score (Grade B, HOLD). The assessment weighs sector, growth, metrics, and analyst views. It is informational and not investment advice

What are realistic near-term price targets for PFE.DE stock

Near-term scenarios show a bullish target of **€24.50** (+11.97%) and a bearish level of **€18.00** (-17.74%). Use earnings and guidance to update targets for PFE.DE stock

DE Stocks

€21.88 Pfizer (PFE.DE XETRA) 29 Jan 2026 ahead of earnings: guidance will set next move

ByHuzaifa Zahoor January 29, 2026January 29, 2026

Pfizer Inc. listed as PFE.DE on XETRA trades at €21.88 intraday on 29 Jan 2026, down -1.97% after an early session pullback as the market focuses on its earnings due 03 Feb 2026. PFE.DE stock faces a short-term test of guidance and sales for its vaccine and specialty portfolios. Volume sits around 39,147.00 shares versus an average of 58,108.00, showing below-average trading ahead of the report. We preview earnings drivers, valuation, and likely market reactions for Germany XETRA traders and EU investors